Mixed inhibition of P450 3A4 as a chemoprotective mechanism against aflatoxin B1-induced cytotoxicity with cis-terpenones

Chemical Research in Toxicology

Volumn 21, Issue 3, 2008, Pages 732-738

  Zhou, Qibing ^a   Zhang, Lin ^a   Zuniga, Miguel A ^a   Tombes, Robert M ^a   Stewart, Jennifer K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYTERPENONE; 4B,5,6,7,8,8A HEXAHYDRO HYDROXY 4B,8,8A TRIMETHYLPHENANTHREN 9,10 DIONE; AFLATOXIN B1; CYTOCHROME P450 3A4; KETOCONAZOLE; TERPENOID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; LIVER TOXICITY;

AFLATOXIN B1; ALGORITHMS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; HYDROLYSIS; INDICATORS AND REAGENTS; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; PHENANTHRENES;

EID: 41849108055     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx700363s     Document Type: Article

References (38)

1. Wilson, D. M., and Payne, G. A. (1994) Factors affecting Aspergillus flavus group infection and aflatoxin contamination of crops. In Toxicology of Aflatoxin: Human Health, Veterinary, and Agricultural Significance (Eaton, D. L. and Groopman, J. D., Eds.) pp 309-326, Academic Press, San Diego, CA.
2. Wang, J. S., Huang, T., Su, J., Liang, F., Wei, Z., Liang, Y., Luo, H., Kuang, S. Y., Qian, G. S., Sun, G., He, X., Kensler, T. W., and Groopman, J. D. (2001) Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. Cancer Epidemiol., Biomarkers Prev. 10, 143-146.
3. 1, and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol., Biomarkers Prev. 10, 617-625.
4. Ming, L., Thorgeirsson, S. S., Gail, M. H., Lu, P., Harris, C. C., Wang, N., Shao, Y., Wu, Z., Liu, G., Wang, X., and Sun, Z. (2002) Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36, 1214-1220.
5. 1 causes guanine substitution in nucleic acids. Nature 267 (5614), 863-865.
6. 1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 90, 8586-8590.
7. 1: Mechanism study. J. Am. Chem. Soc. 116, 1603-1609.
8. 1-DNA adduct. Proc. Natl. Acad. Sci. U.S.A. 93, 1535-1539.
9. 1. Free Radic. Res. Commun. 10, 137-142.
10. 1-induced cell injury in cultured rat hepatocytes. Toxicology 99, 115-123.
11. 1. Free Radical Biol. Med. 21, 139-146.
12. NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. U.S.A. 86, 462-465.
13. 1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11, 2275-2279.
14. 1. Chem. Res. Toxicol. 5, 202-210.
15. 1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8, 218-225.
16. 1 exo-8,9-epoxide and rearrangement of the dihydrodiol. J. Am. Chem. Soc. 118, 8213-8220.
17. 1-exo-8,9-epoxide with DNA: Kinetic analysis of covalent binding and DNA induced hydrolysis. Proc. Natl. Acad. Sci. U.S.A. 94, 6121-6125.
18. 1. Mutat. Res. 402, 121-128.
19. Guengerich, F. P. (2003) Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch. Biochem. Biophys. 409, 59-71.
20. 1. Cancer Res. 54, 101-108.
21. 1. Chem. Res. Toxicol. 19, 577-586.
22. Kensler, T. W., Egner, P. A., Wang, J. B., Zhu, Y. R., Zhang, B. C., Lu, P. X., Chen, J. G., Qian, G. S., Kuang, S. Y., Jackson, P. E., Gange, S. J., Jacobson, L. P., Munoz, A., and Groopman, J. D. (2004) Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127, S310-S318.
23. Egner, P. A., Kensler, T. W., Prestera, T., Talalay, P., Libby, A. H., Joyner, H. H., and Curphey, T. J. (1994) Regulation of phase 2 enzyme induction by oltipraz and other dithiolethione. Carcinogenesis 15, 177-181.
24. 1 metabolism in human hepatocytes in primary culture. Cancer Res. 95, 5574-5579.
25. Kensler, T. W., He, X., Otieno, M., Egner, P. A., Jacobson, L. P., Chen, B., Wang, J. S., Zhu, Y. R., Zhang, B. C., Wang, J. B., Wu, Y., Zhang, Q. N., Qian, G. S., Kuang, S. Y., Fang, X., Li, Y. F., Yu, L. Y., Prochaska, H. J., Davidson, N. E., Gordon, G. B., Gorman, M. B., Zarba, A., Enger, C., Munoz, A., and Helzlsouer, K. J. (1998) Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol., Biomarkers Prev. 7, 127-134.
26. Zhang, B. C., Zhu, Y. R., Wang, J. B., Wu, Y., Zhang, Q. N., Qian, G. S., Kuang, S. Y., Li, Y. F., Fang, X., Yu, L. Y., De Flora, S., Jacobson, L. P., Zarba, A., Egner, P. A., He, X., Wang, J. S., Chen, B., Enger, C. L., Davidson, N. E., Gordon, G. B., Gorman, M. B., Prochaska, H. J., Groopman, J. D., Munoz, A., and Kensler, T. W. (1997) Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China. J. Cell Biochem. Suppl. 28, 166-173.
27. Jacobson, L. P., Zhang, B. C., Zhu, Y. R., Wang, J. B., Wu, Y., Zhang, Q. N., Yu, L. Y., Qian, G. S., Kuang, S. Y., Li, Y. F., Fang, X., Zarba, A., Chen, B., Enger, C. L., Davidson, N. E., Gorman, M. B., Gordon, G. B., Prochaska, H. J., Egner, P. A., Groopman, J. D., Munoz, A., Helzlsouer, K. J., and Kensler, T. W. (1997) Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol, Biomarkers Prev. 6, 257-265.
28. Egner, P. A., Wang, J. B., Zhu, Y. R., Zhang, B. C., Wu, Y., Zhang, Q. N., Qian, G. S., Kuang, S. Y., Gange, S. J., Jacobson, L. P., Helzlsouer, K. J., Bailey, G. S., Groopman, J. D., and Kensler, T. W. (2001) Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl. Acad. Sci. U.S.A. 98, 14601-14606.
29. 1: Complex formation with the carcinogen. Chem. Res. Toxicol. 8, 506-514.
30. 1 across Caco-2 cell monolayers. Toxicology 196, 117-125.
31. 1 induced cytotoxicity and TCDD-induced P450 1A/B activity in HepG2 Cells. Chem. Res. Toxicol. 19, 1415-1419.
32. 2+-induced oxidation of a diterpenone catechol and concurrent damage on DNA. Chem. Res. Toxicol. 18, 382-388.
33. Zuniga, M. A., Dai, J., Wehunt, M. P., and Zhou, Q. (2006) DNA oxidative damage by terpene catechols as analogs of natural terpene quinone methide precursors in the presence of Cu (II) and/or NADH. Chem. Res. Toxicol. 19, 828-836.
34. Guengerich, F. P. (2005) Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano, P. R., Eds.) 3rd ed., pp 377-530, Kluwer Academic/ Plenum Publishers, New York.
35. Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., and Guengerich, F. P. (1997) Cooperativity in oxidation catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381.
36. Westerink, W. M. A., and Schoonen, W. G. E. J. (2007) Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21, 1581-1591.
37. Rodriguez, R. J., and Acosta, D. (1995) Comparison of ketoconazole-and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 96, 83-92.
38. Buchi, K. N., Gray, P. D., and Tolman, K. G. (1986) Ketoconazole hepatotoxicity: An in vitro model. Biochem. Pharmacol. 35, 2845-2847.